Nos actions
et publications.

Retrouver les travaux du club, ses initiatives collectives et ses contributions scientifiques.

Nos actions Nos publications

01 / VIE SCIENTIFIQUE

Nos actions

01
Cartographie des centres
Cartographie des centres proposant des CAR-T cells et des T-cell engagers dans le cadre d’études cliniques, en collaboration avec FAI2R.
02
Information des patients
Carte d’urgence et document d’information destinés aux patients traités par CAR-T cells.
03
Formations et webinaires
Formations et webinaires autour des thérapies innovantes dans les IMIDs.

02 / CONTRIBUTIONS SCIENTIFIQUES

Nos publications

Suspected ICANS in systemic sclerosis: think twice before corticosteroids
Boyer M, Sebbag E, Collongues N, Florens N, Storck W, El-Aatmani A, Walther J, Castelain V, Mariaseelan S, Grass L, Sibilia J, Gottenberg JE, Scherlinger M.
Rheumatology. 2026;65(9):keag485.
DOI : 10.1093/rheumatology/keag485 PubMed
Immune reset after deep B-lineage depletion: remission is not reprogramming Accès libre
Scherlinger M, Avouac J, Tsokos GC.
Annals of the Rheumatic Diseases. 2026 Sep 3:S0003-4967(26)00473-5. Publication en ligne avant attribution à un numéro.
DOI : 10.1016/j.ard.2026.07.016 PubMed
The why, what, who and when of B cell depletion in systemic lupus erythematosus: biological rationale, patient stratification and evolving therapeutic modalities Accès libre
Wincup C, Gatto M, Scherlinger M, Schett G, Hagen M.
Rheumatology. 2026;65(8):keag416.
DOI : 10.1093/rheumatology/keag416 PubMed
Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series Accès libre
Scherlinger M, Dieudonné Y, Hilliquin S, Chatelus E, d'Alessandro R, Gies V, Nespola B, Martin T, Gottenberg JE, Simand C, El Aatmani A, Brandely-Piat ML, Sebbag E, Decroocq J, Sibilia J, Allanore Y, Avouac J.
Annals of the Rheumatic Diseases. 2026;85(6):1172–1179.
DOI : 10.1016/j.ard.2026.02.002 PubMed
Roads and detours for CAR T cell therapy in autoimmune diseases
Avouac J, Barzel A, Caiati D, Davis RS, Gottschalk S, Grieshaber-Bouyer R, Mao X, Luning Prak ET, Radic M, Scherlinger M, Suneja Y, Talleur A, Thacker AL, Unutmaz D.
Nature Reviews Drug Discovery. 2026;25(4):290–309.
DOI : 10.1038/s41573-025-01349-4 PubMed
CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future? Accès libre
Jouret M, Viel S, Fournier B, Benezech S, Avouac J, Scherlinger M, Belot A; C3I consortium.
Arthritis Research & Therapy. 2025;27(1):102.
DOI : 10.1186/s13075-025-03564-1 PubMed
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
Scherlinger M, Nocturne G, Radic M, Launay D, Richez C, Bousso P, Forcade E, Meyer A, Jorgensen C, Bigenwald C, Cornec D, Sibilia J, Choquet S, Martin T, Belot A, Jouret M, Bitoun S, Amoura Z, Hermine O, Mariette X, Donnadieu E, Avouac J; Club for Innovative Immunotherapies in Immune-mediated Inflammatory diseases (C3I).
The Lancet Rheumatology. 2025;7(6):e434–e447.
DOI : 10.1016/S2665-9913(24)00377-1 PubMed

Découvrir celles et ceux qui portent la réflexion du club.

Les comités du C3I

Nos actionset publications.

Nos actions

Cartographie des centres

Information des patients

Formations et webinaires

Nos publications

Suspected ICANS in systemic sclerosis: think twice before corticosteroids

Immune reset after deep B-lineage depletion: remission is not reprogramming Accès libre

The why, what, who and when of B cell depletion in systemic lupus erythematosus: biological rationale, patient stratification and evolving therapeutic modalities Accès libre

Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series Accès libre

Roads and detours for CAR T cell therapy in autoimmune diseases

CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future? Accès libre

CAR T-cell therapy in autoimmune diseases: where are we and where are we going?

Nos actions
et publications.